Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3500

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Hematologic Malignancies

Interventions

DRUG: Pembrolizumab
DRUG: Standard of Care (SOC)
DRUG: Lenvatinib
DRUG: Olaparib
DRUG: MK-4280
BIOLOGICAL: MK-4280A
BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa

Sponsor

Merck Sharp & Dohme LLC